

LITERATURA

1. Sawicki T, Ruszkowska M, Danielewicz A, et al. Review of Colorectal Cancer in Terms of Epidemiology, Risk Factors, Development, Symptoms and Diagnosis. *Cancers*. 2021;13(9):2025.
2. Sinicrope FA. Increasing Incidence of Early-Onset Colorectal Cancer. *N Engl J Med*. 2022;386(16):1547-1558. doi: 10.1056/NEJMra2200869. PMID: 35443109.
3. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. *N. Engl. J. Med*. 2012;366(26):2443-2454. <https://doi.org/10.1056/NEJMoa1200690>.
4. Gelsomino F, Barbolini M, Spallanzani A, et al. The evolving role of microsatellite instability in colorectal cancer: A review. *Cancer Treat Rev*. 2016;51:19-26.
5. Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. *N. Engl. J. Med*. 2015;372(26):2509-2520. <https://doi.org/10.1056/NEJMoa1500596>.
6. O'Neil BH, Wallmark JM, Lorente D, et al. Safety and anti-tumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma. *PLoS One*. 2017;12(12):e0189848. doi: 10.1371/journal.pone.0189848. PMID: 29284010; PMCID: PMC5746232.
7. Kai-Keen S, Thierry A, Tae Won K, et al. KEYNOTE-177: Phase III randomized study of pembrolizumab versus chemotherapy for microsatellite instability-high advanced colorectal cancer. *Journal of Clinical Oncology*. 2021 39:3suppl. 6-6.
8. Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. *Lancet Oncol*. 2017;18(9):1182-1191. doi: 10.1016/S1470-2045(17)30422-9. Epub 2017 Jul 19. Erratum in: *Lancet Oncol*. 2017;18(9):e510. PMID: 28734759; PMCID: PMC6207072.
9. Overman MJ, Lonardi S, Wong KYM, et al. Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. *J Clin Oncol*. 2018;36(8):773-779. doi: 10.1200/JCO.2017.76.9901. Epub 2018 Jan 20. PMID: 29355075.
10. Available from: <https://clinicaloptions.com/CE-CME/oncology/checkmate-142-5-yr-update/100002202-100003196>.
11. André T, Van Cutsem E, Eleaz E, et al. P-12 A phase 3 study of nivolumab (NIVO), NIVO + ipilimumab (IPI), or chemotherapy for microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): CheckMate 8HW. *Annals of Oncology*. 2022;33:S250.
12. Eng C, Kim TW, Bendell J, et al. IMblaze370 Investigators. Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. *Lancet Oncol*. 2019;20:849-861.
13. Overman MJ, Kopetz S, McDermott RS, et al. Nivolumab ± ipilimumab in treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): CheckMate-142 interim results. *J Clin Oncol*. 2016;34:15suppl; abstr. 3501.
14. Cousin S, Cantarel C, Guegan J-P, et al. Regorafenib-avelumab combination in patients with microsatellite stable colorectal cancer (REGOMUNE): a single-arm, open-label, phase II trial. *Clin Cancer Res*. 2021;27:2139-2147.
15. Morris VK, Parseghian CM, Escano M, et al. Phase I/II trial of encorafenib, cetuximab, and nivolumab in patients with microsatellite stable, BRAF V600E metastatic colorectal cancer. 2022 ASCO Gastrointestinal Cancers Symposium. 2022; January 22: Abstract 12.
16. Kawazoe A, Xu R, Passhak M, et al. Lenvatinib plus pembrolizumab versus standard of care for previously treated metastatic colorectal cancer (mCRC): the phase 3 LEAP-017 study. *Ann Oncol*. 2023;34(Suppl 1):S179. doi:10.1016/j.annonc.2023.04.015.
17. Saberzadeh-Ardestani B, Jones JC, Hubbard JM, et al. Association Between Survival and Metastatic Site in Mismatch Repair-Deficient Metastatic Colorectal Cancer Treated With First-line Pembrolizumab. *JAMA Netw Open*. 2023;6(2):e230400. doi:10.1001/jamanetworkopen.2023.0400.
18. Antoniotti C, Rossini D, Pietrantonio F, et al. FOLFOXIRI plus bevacizumab and atezolizumab as upfront treatment of unresectable metastatic colorectal cancer (mCRC): Updated and overall survival results of the phase II randomized AtezoTRIBE study. Presented at ASCO Annual Meeting. 2023; Chicago: June 2-6: abstract 3500.
19. Lenz HJ, Raj Parikh A, Spigel DR, et al. Nivolumab (NIVO) + 5-fluorouracil/leucovorin/oxaliplatin (mFOLFOX6)/bevacizumab (BEV) versus mFOLFOX6/BEV for first-line (1L) treatment of metastatic colorectal cancer (mCRC): Phase 2 results from CheckMate 9X8. *Journal of Clinical Oncology*. 2022;40:4_suppl, 8-8.
20. Conca V, Antoniotti C, Bergamo F, et al. Modified FOLFOXIRI plus cetuximab and avelumab as initial therapy in RAS wild-type unresectable metastatic colorectal cancer: Results of the phase II AVETRIC trial by GONO. *Journal of Clinical Oncology*. 2023;41:16_suppl.:3575-3575.
21. Folprecht G, Mende M, Liersch T, et al. Cetuximab/FOLFIRI +/- oxaliplatin or FOLFOXIRI +/- bevacizumab in patients with colorectal cancer and liver metastases (AIO CELIM2- study). *J Clin Oncol*. 2020;38:abstract 4024.
22. Hu H, Wang K, Huang M, et al. Modified FOLFOXIRI with or without cetuximab as conversion therapy in patients with RAS/BRAF wild-type unresectable liver metastases colorectal cancer: the FOCULM multicenter phase II trial *Oncologist*. 2021;26:e90-e98.
23. Domingo E, Freeman-Mills L, Rayner E, et al. Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study. *Lancet Gastroenterol Hepatol*. 2016;1(3):207-216. doi: 10.1016/S2468-1253(16)30014-0. Epub 2016 Jul 20. PMID: 28404093.
24. Wang F, Zhao Q, Wang Y, et al. Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types. *JAMA Oncol*. 2019;5(10):1504-1506. doi:10.1001/jamaoncol.2019.2963.
25. Vanderwalde A, Spetzler D, Xiao N, et al. Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients. *Cancer Med*. 2018;7:746-756. <https://doi.org/10.1002/cam4.1372>.
26. Rousseau B, Foote MB, Maron SB, et al. The spectrum of benefit from checkpoint blockade in hypermutated tumors. *N Engl J Med*. 2021;384:1168-1170.
27. WCGIC 2023, LBA-4. Available from: https://agenusbio.com/wp-content/uploads/2023/06/15Jun2023_Bullock_ESMO-GI-Oral-Presentation_FINAL.pdf.
28. Morano F, Raimondi A, Pagani F, et al. Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O6-Methylguanine-DNA Methyltransferase-Silenced Metastatic Colorectal Cancer: The MAYA Trial. *J Clin Oncol*. 2022;40(14):1562-1573. doi: 10.1200/JCO.21.02583. Epub 2022 Mar. 8.

Onkologie
www.onkologiecs.cz

